Rituximab biosimilar (Innovent Biologics)

利妥昔单抗生物类似药（信达生物）

Report date: 2023/05/05 17:34:43

Base Information

Drug NameRituximab biosimilar (Innovent Biologics)
Drug Alias NameRituximab (Innovent Biologics)利妥昔单抗生物仿制药 (Innovent Biologics)美罗华生物仿制药 (Innovent Biologics)Rituximabum (Innovent Biologics)利妥昔单抗 (Innovent Biologics) +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmAnemiaHematologic Neoplasms +[19] 
Global Approved IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryMainland China
Original Approved Date2020/09/30
Country/TerritoryCanadaUnited StatesPuerto Rico +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesRutgers University
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmAnemiaHematologic Neoplasms +[13] 
Inactive IndicationsLymphoma, T-CellLymphoma, Mantle-CellLymphoma, B-Cell, Marginal Zone +[6] 

Other Information

ATC CodeL01XC02
Related LinksN/A